Home » NHS » Page 3

New Drugs Offer Hope in Battling Silent Kidney Disease Epidemic

Health Officials are warning of a looming crisis as chronic kidney disease cases surge, now impacting over seven million individuals in Britain and contributing to 45,000 deaths annually. This silent epidemic, frequently enough undetected in its early stages, poses a significant threat to public health and places an immense strain on healthcare systems.

The Growing Burden of Kidney Disease

Experts describe the situation as a “slow-moving tidal wave,” with the number of diagnoses expected to rise by 400,000 over the next decade. The financial implications are staggering, with dialysis – a lifesaving but intensive treatment – already costing the National Health Service billions of pounds each year, a figure projected to reach £13 billion annually by the end of the decade. Furthermore, the waitlist for kidney transplants is expected to triple by 2033, leaving nearly 1,000 individuals dying each year while awaiting a donor organ.

Several factors are driving this increase, including an ageing population and the rising prevalence of high blood pressure. However, the most significant contributor is the dramatic increase in diabetes cases, which have doubled in the last 20 years and are predicted to climb by another million by 2030. Consistently elevated blood sugar levels inevitably damage the kidneys, with nearly four in ten diabetes patients developing kidney disease, and a third progressing to organ failure.

A Breakthrough in Treatment: SGLT2 Inhibitors

For years, the approach to kidney disease has centered on prevention and early detection, as damage was considered irreversible.However, a new class of drugs – SGLT2 inhibitors – is being hailed as a revolutionary breakthrough, offering a potential to not only slow progression but also protect against further damage. These tablets, costing around £1 per day, are now considered by some specialists to be a greater advancement than recent weight-loss medications like Wegovy and Mounjaro.

Earlier this month, the NHS announced expanded access to SGLT2 inhibitors for millions of patients through their primary care physicians. These medications, including empagliflozin (Jardiance), dapagliflozin (Forxiga), canagliflozin and ertugliflozin, work by blocking the absorption of sugar and salt in the kidneys, flushing them out through urine and reducing the burden on kidney function. Recent research indicates that these drugs also possess anti-inflammatory properties, protecting both the kidneys and the heart.

Drug Name Primary Action Key Benefits
Empagliflozin (Jardiance) Blocks sugar/salt absorption slows kidney disease progression by ~40%, reduces heart disease risk.
Dapagliflozin (Forxiga) Blocks sugar/salt absorption Similar benefits to Empagliflozin.
Canagliflozin Blocks sugar/salt absorption Similar benefits to Empagliflozin and Dapagliflozin.
Ertugliflozin Blocks sugar/salt absorption Similar benefits to Empagliflozin and Dapagliflozin.

Did you know? SGLT2 inhibitors have shown to reduce the risk of heart disease and death from cardiovascular problems by approximately a third.

Studies have repeatedly shown the efficacy of these drugs, reducing the risk of needing dialysis or a transplant by as much as a quarter. They are now also being prescribed to patients with severe kidney disease,even without a diabetes diagnosis.

Challenges and Access

While the new NHS guidance recommends offering SGLT2 inhibitors immediately after a diabetes diagnosis, alongside metformin, experts caution that many physicians remain unaware of their benefits. fiona Loud, policy director at Kidney Care UK, warns that “the number of kidney disease patients getting these drugs is worryingly low,” and urges GPs to familiarize themselves with the latest guidance. Ensuring widespread awareness and access is crucial to maximizing the impact of this perhaps life-saving treatment.

A Patient’s Story

Mary Cooper, 82, from Milton Keynes, participated in a trial for empagliflozin in 2018 after being diagnosed with advanced kidney disease 15 years prior. After five years on the medication, her kidney function remained stable, preventing the need for dialysis or a transplant. She eagerly awaits the possibility to continue the treatment through her GP.

Understanding Chronic Kidney Disease

Chronic Kidney Disease (CKD) is a progressive condition where the kidneys lose their ability to filter waste and excess fluids from the blood. Early stages often have no symptoms, making regular check-ups vital, especially for those with diabetes, high blood pressure, or a family history of kidney disease. Maintaining a healthy lifestyle, including a balanced diet and regular exercise, can significantly reduce your risk.


What do you think about the potential of these new drugs to transform kidney disease treatment? Do you think awareness among GPs is sufficient to ensure patients benefit from these advances?

Disclaimer: This article provides general facts and should not be considered medical advice. Always consult with a healthcare professional for diagnosis and treatment of any health condition.

Share this article with your network to raise awareness about kidney disease and the hope offered by these new treatments. Leave a comment below to share your thoughts.

What are the five main types of Pulmonary hypertension, and what distinguishes each one?

Silent Killer Affecting Millions: The £1 Pill That Could Prevent More Deaths Then Breast and Prostate Cancer Combined

Understanding Pulmonary Hypertension: The Hidden Threat

Pulmonary hypertension (PH) is a progressive and life-limiting condition affecting the arteries in the lungs and the right side of the heart. Often dubbed a “silent killer,” it frequently goes undiagnosed for months, even years, because early symptoms mimic those of other, less serious conditions like fatigue or shortness of breath. This delay in diagnosis substantially impacts treatment outcomes. The potential to prevent more deaths than breast and prostate cancer combined stems from the increasing evidence of underdiagnosis and the availability of a relatively inexpensive, life-extending treatment – sildenafil.

What Exactly Is Pulmonary Hypertension?

Normally, blood flows smoothly through the lungs to pick up oxygen.In PH, the pulmonary arteries become narrowed, blocked, or destroyed. This makes it harder for blood to flow through, increasing blood pressure in the lungs and forcing the heart to work harder. Over time, this strain can lead to heart failure and other serious complications. There are five main types of PH:

  1. Pulmonary Arterial Hypertension (PAH): The most common form, often idiopathic (meaning the cause is unknown) but can be linked to genetics, certain medications, or connective tissue diseases.
  2. PH due to Left Heart Disease: The most frequent cause resulting from problems with the left side of the heart.
  3. PH due to Lung Diseases and/or Hypoxia: Caused by chronic obstructive pulmonary disease (COPD), interstitial lung disease, or sleep apnea.
  4. Chronic thromboembolic Pulmonary Hypertension (CTEPH): Develops after a blood clot in the lungs has not been fully resolved.
  5. PH with Unclear Multifactorial Mechanisms: A less common category encompassing various causes.

The Role of Sildenafil: A Game Changer in PH Management

Sildenafil,commonly known by the brand name Viagra,isn’t just for erectile dysfunction. It’s a potent vasodilator – meaning it widens blood vessels – and has proven remarkably effective in treating pulmonary arterial hypertension (PAH). The cost of a generic sildenafil tablet can be as low as £1, making it an incredibly accessible treatment option.

How Sildenafil Works in the Lungs

Sildenafil works by inhibiting an enzyme called phosphodiesterase type 5 (PDE5). This enzyme breaks down a molecule called cyclic GMP,which relaxes smooth muscle cells in the blood vessels. By blocking PDE5, sildenafil allows cyclic GMP to accumulate, leading to vasodilation in the pulmonary arteries, reducing pulmonary artery pressure, and easing the workload on the heart.

clinical Evidence & Impact on Mortality

Numerous clinical trials have demonstrated the benefits of sildenafil in PAH. Studies show:

Improved Exercise Capacity: Patients treated with sildenafil experience a important increase in their ability to exercise without becoming breathless.

Reduced Pulmonary Artery Pressure: A measurable decrease in the pressure within the pulmonary arteries.

Delayed Disease Progression: Sildenafil can slow down the worsening of PH symptoms and improve quality of life.

Increased Survival Rates: While not a cure, sildenafil has been shown to improve survival rates in PAH patients, especially when used in combination with other therapies.

Recognizing the Symptoms: Early Detection is Key

Because PH symptoms are often non-specific, diagnosis can be challenging. Being aware of the potential warning signs is crucial. Common symptoms include:

Shortness of breath, especially during exercise.

Fatigue.

Dizziness or fainting.

Chest pain.

Swelling in the ankles, legs, and abdomen.

Bluish color of the lips and skin (cyanosis).

If you experience any of these symptoms,especially if they are worsening,it’s vital to consult a doctor.

Diagnosis & Testing: What to Expect

Diagnosing PH involves a combination of tests:

Echocardiogram: An ultrasound of the heart to assess heart function and estimate pulmonary artery pressure.

Pulmonary Function Tests (PFTs): Assess lung capacity and airflow.

Right heart Catheterization: The gold standard for diagnosing PH. This invasive procedure directly measures pressures in the pulmonary arteries and heart.

Blood Tests: To rule out other conditions and assess overall health.

CT Scan: To identify any underlying lung disease.

Risk Factors & Prevention

While not all cases of PH are preventable, understanding the risk factors can help with early detection and management:

Family History: A genetic predisposition can increase your risk.

Connective tissue Diseases: Conditions like scleroderma, lupus, and rheumatoid arthritis.

HIV Infection.

Liver Disease.

Certain Medications & Drugs.

Sleep Apnea: Untreated sleep apnea can contribute to PH.

Chronic Lung Conditions: COPD and interstitial lung disease.

The £1 Pill & Global Health

0 comments
0 FacebookTwitterPinterestEmail

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.